Current preclinical oncology models are constrained by a fundamental trade-off: physiologically relevant 3D tumor systems that incorporate circulating immune or therapeutic cells—and, ideally, multi-organ crosstalk—lack the throughput needed for drug screening and personalized therapy development. Conversely, high-throughput platforms typically rely on oversimplified 2D cultures that fail to recapitulate the dynamic tumor microenvironment, immune infiltration, or systemic interactions.

React4Life overcomes this limitation with an advanced platform centered on its patented MIVO® technology: the first integrated MIVO®-based cancer-on-chip system featuring the TOKYO fluidic module, capable of simultaneously supporting:
(i) long-term 3D culture of patient-derived tumor biopsies, preserving native stromal and cellular heterogeneity;
(ii) continuous perfusion with circulating cells (e.g., immune cells, therapeutic agents, or cellular carriers) under tumor-relevant capillary flow velocities (0.1–1 mm/s);
(iii) modular multi-organ connectivity for modeling tumor–organ crosstalk and metastatic dissemination; and
(iv) true high-throughput experimental capacity, enabled by the TOKYO fluidic module with 24 independently controlled parallel lines.

The React4Life platform integrates the physiological fidelity of MIVO®—which recapitulates dynamic perfusion, tissue–cell crosstalk, and vascular-like flow—with the scalable fluidic architecture of the TOKYO module. This combination enables robust monitoring of tumor response, circulating cell interactions, and resistance mechanisms in a human-relevant microenvironment. Validation using patient-derived samples demonstrates 92–95% concordance with clinical drug responses—significantly outperforming conventional 2D cultures.

As the only system that simultaneously supports 3D tumor complexity, dynamic circulating cell exposure, multi-organ connectivity, and high-throughput experimental scalability, the React4Life platform establishes a new standard for immuno-oncology, metastasis research, and patient-tailored therapeutic development.